SABCS 2019: PROMIS Clinical Risk

AUTHORS:

Michaela Tsai, Hatem Soliman, Shelly Lo, Rubina Qamar, Raye Budway, Ellis Levine, Pat Whitworth, Blanche Mavromatis, Robin Zon, Sarah Untch1, Lisa Blumencranz, Joseph McKelley, William Audeh, PROMIS Investigators Group

DESCRIPTION:

Treatment recommendations in ER+ patients ≤ 50 years: comparison of the 21-gene assay and 70-gene signature in the PROMIS study

The PROMIS trial previously evaluated how a definitive result from the MammaPrint 70-gene signature (70-GS) can impact treatment recommendations for patients with an intermediate range recurrence score (RS 18-30) from the 21-gene assay. This current analysis examines the updated treatment recommendations based on the interaction between patient age and clinical risk and explores the impact that the 70-GS can have on adjuvant chemotherapy decisions for women ≤50 years of age.